

Changes to Genetic Signatures' Board of Directors

Genetic Signatures [ASX:GSS] ("GSS" or "the Company"), a global molecular diagnostics company is today announcing the following planned succession changes to its Board of Directors:

- the appointment of Ms Anne Lockwood as a Non-Executive Director on 1 October 2024;
- the resignation of current Non-Executive Director Dr Tony Radford;
- the retirement of Dr Nick Samaras at the Company's Annual General Meeting on 20 November 2024; and
- the appointment of Ms Caroline Waldron as Chair following the Company's 2024 Annual General Meeting on 20 November 2024.

Incoming Director, Ms Lockwood, is currently a Non-Executive Director for the ASX-listed company Mayne Pharma and Chief Financial Officer for Planet Innovation. She brings strong finance and accounting as well as US operations experience gained from senior executive roles in healthcare and life science companies. Ms Lockwood will join the Board effective 1 October 2024.

Dr Tony Radford has retired from the Board effective immediately in order to reduce his work commitments and focus on personal and family activities. As a recognised leader in the Australian diagnostics space, Dr Radford has been a highly valued Non-Executive Director of Genetic Signatures since September 2015.

After 16 years of dedicated service, Dr Nick Samaras has advised that he intends to resign from the Board at the Company's upcoming Annual General Meeting. Dr Samaras has guided the Company through its transformation from a research-based organisation to a fully-fledged commercial Company with revolutionary molecular diagnostic products approved in multiple markets around the globe.

Current Non-Executive Director Ms Caroline Waldron will take up the role of Chair following Dr Samaras' retirement at the Annual General Meeting. The Company is also in the process of recruiting an additional Director to the Board with commercialisation experience.

*"The Board changes have been planned to coincide with the next phase of the Company's growth and commercial development following the recent FDA clearance of our EasyScreen™ Gastrointestinal Parasite Detection Kit in June of this year" said **Nick Samaras, outgoing Chair of Genetic Signatures**. "We are delighted to secure Ms Lockwood as a Director, particularly in light of her strong finance and healthcare background. I would also like to sincerely thank Dr Radford for his invaluable contributions over many years which have been instrumental in making Genetic Signatures the successful Company that it is today."*

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr Neil Gunn

Interim Chief Executive Officer

neil.gunn@geneticsignatures.com

Karl Pechmann

Chief Financial Officer

karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures' proprietary MDx 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen*™ respiratory kits and the growing interest in its gastroenteritis products to further commercialise its 3base® technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.